Trelegy Ellipta vs Symbicort
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Trelegy Ellipta | US Symbicort | |
|---|---|---|
| Generic name | fluticasone/umeclidinium/vilanterol | budesonide/formoterol |
| Drug class | Inhaled Corticosteroid + LAMA + LABA | ICS/LABA Inhaler |
| Treats | COPD, asthma | Asthma, COPD |
| Category | Respiratory | Respiratory |
| Manufacturer | GSK | AstraZeneca |
| Year approved | 2017 | 2006 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $200M | $120M |
| Common side effects | Thrush, Respiratory infections, Headache, Cough | Throat irritation, Oral thrush, Hoarseness, Headache |
Trelegy Ellipta
Symbicort
Frequently asked questions
Is Trelegy Ellipta or Symbicort better?
Neither is universally "better." Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) and Symbicort (budesonide/formoterol) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Trelegy Ellipta and Symbicort?
Trelegy Ellipta is a Inhaled Corticosteroid + LAMA + LABA made by GSK, while Symbicort is a ICS/LABA Inhaler made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Trelegy Ellipta has the larger estimated TV advertising budget of the two.